Schultz Jerette J, Naides Alexandra I, Bai Di, Shulzhenko Nikita O, Keith Jonathan D
Division of Plastic and Reconstructive Surgery, Department of Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
East Coast Advanced Plastic Surgery, Livingston, New Jersey, USA.
Transgend Health. 2021 Dec 2;6(6):353-357. doi: 10.1089/trgh.2020.0108. eCollection 2021 Dec.
The rate of masculinizing chest surgery for gender affirmation continues to increase. With a paucity of literature on pathological evaluation of breast specimens in this patient population, there is a need for these data and for protocols on the handling of these specimens. A retrospective chart review was performed between 2015 and 2020 on all patients who underwent chest masculinization surgery for gender dysphoria by the senior author (J.D.K.). Inclusion criteria were any patient with sex assigned female at birth who underwent removal of breast and/or nipple areolar complex tissue for gender affirmation. Patient demographics were recorded. Bilateral breast tissue was sent for routine pathology in all cases and findings were recorded. A -value of <0.05 was considered significant. Seventy-four consecutive patients and 148 breast specimen reports were identified from a database and included in the study. The mean age was 26 years (15-49). Thirty-nine patients had a known history of chest wall binding and 60 patients had undergone preoperative androgen therapy. There was no invasive or in situ carcinoma found in any breast tissue specimens. Thirty-four patients had a benign lesion in one or both breast specimens. Atypical lobular hyperplasia was found in one patient's specimen. A history of chest wall binding was not correlated with any benign lesions (=0.79) or stromal fibrosis (=0.94). A history of testosterone use was not correlated with any benign lesions (=0.35) or stromal fibrosis (=0.20). The prevalence (1.4%) of significant breast pathology and of benign findings (46%) in our study closely correlates with the rates in the literature. We found no correlation between significant breast pathology or benign lesions and a history of chest wall binding or preoperative androgen therapy. We recommend all breast specimens removed during chest masculinization surgery be sent for pathological evaluation.
用于性别肯定的男性化胸部手术的比率持续上升。鉴于关于该患者群体乳腺标本病理评估的文献匮乏,需要获取这些数据以及关于这些标本处理的方案。资深作者(J.D.K.)对2015年至2020年间所有因性别焦虑症接受胸部男性化手术的患者进行了回顾性病历审查。纳入标准为所有出生时被指定为女性且因性别肯定而接受乳房和/或乳头乳晕复合体组织切除的患者。记录了患者的人口统计学信息。所有病例均将双侧乳腺组织送去做常规病理检查并记录结果。P值<0.05被认为具有统计学意义。从数据库中识别出74例连续患者和148份乳腺标本报告并纳入研究。平均年龄为26岁(15 - 49岁)。39例患者有已知的胸壁束缚史,60例患者接受过术前雄激素治疗。在任何乳腺组织标本中均未发现浸润性癌或原位癌。34例患者在一侧或双侧乳腺标本中有良性病变。在一名患者的标本中发现了非典型小叶增生。胸壁束缚史与任何良性病变(P = 0.79)或间质纤维化(P = 0.94)均无相关性。使用睾酮的病史与任何良性病变(P = 0.35)或间质纤维化(P = 0.20)均无相关性。我们研究中显著乳腺病理的患病率(1.4%)和良性发现的患病率(46%)与文献中的比率密切相关。我们发现显著乳腺病理或良性病变与胸壁束缚史或术前雄激素治疗之间无相关性。我们建议将胸部男性化手术中切除的所有乳腺标本送去做病理评估。